TissueTech’s Bio-Tissue Awarded Minority Business of the Year

Bio-Tissue® Inc, the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, today announced it has been selected as Minority Business of the Year  – Large (50 employees or more) by the Greater Miami Chamber of Commerce 2014 Top Minority Business Awards.  The award was presented to Bio-Tissue®’s President and CEO Amy Tseng by Bank of America, Greater Miami Chamber of Commerce, at the 2014 Top Minority Business Awards luncheon on Wednesday, April 9, 2014.

“We are honored to be recognized by the Greater Miami Chamber of Commerce for our exemplary business performance and contributions to the growth of the community,” said Amy Tseng, President and CEO, Bio-Tissue® Inc, a subsidiary of TissueTech™.  “Our company is committed to recruiting and retaining a talented and diverse workforce which has played a key part in our success, rapid growth, and involvement in the South Florida community.”

Bio-Tissue® and its parent company TissueTech™ are led by a woman and minority President and CEO Amy Tseng.  She and her husband Scheffer C. G. Tseng, MD, PhD, Bio-Tissue® Inc Chairman and Chief Scientific Officer, founded TissueTech™ and Bio-Tissue® in 1997 with the vision of advancing the treatment of ocular surface diseases. Since then, the company has grown to 154 employees throughout the United States, 80 percent of whom are minorities. In addition to a woman CEO, nearly half of its management team are women, and its employees come from diverse backgrounds, experiences, and ethnicities.

Bio-Tissue® continues to experience year to year growth in a competitive biotech landscape and in January 2014 announced it had attained a 7-year compounded annual growth rate (CAGR) of 35 percent. In 2013 the company added approximately 40 percent to its workforce. With nearly 200,000 units shipped across all product lines since 2006 and more than 150,000 successful human transplantations, Bio-Tissue®’s products are used by eye care professionals worldwide to manage ocular surface diseases and conditions.